HealthX Connect Osaka 2026

1 Jul 2026 | Osaka, Japan

Register
Register
Register

Innodem Neurosciences

Company (SME/startup) / 中小企業・スタートアップ

innodemneurosciences.comMontreal, Canada
7 profile visits

About

Who we are

Co-founded by cognitive neurologist Dr. Étienne de Villers-Sidani (UCSF/McGill University), software engineer Yves Desgagné and neurologist Dr. Paul Giaccomini, INNODEM NEUROSCIENCES is a private company created in 2016 and backed by private investors. The company received FDA Breakthrough Device Designation for its ETNA-MS (Eye Tracking Neurological Assessment for Multiple Sclerosis) patented technology and received Health Canada clearance in early Q1-24 for their first product ETNA-MS, offering MS patients a non-invasive digital way to monitor the progression of their disease.

Preliminary clinical trial results have been peer-reviewed and are available in the publication Frontiers of Neurology. The company has already signed partnering agreements with Novartis Pharmaceuticals Canada Inc. including a commercial framework agreement. Other pharmaceutical partnership agreements are in the works and will be announced during the year.

What we do

Innodem Neurosciences is a digital biomarker & AI company that specializes in the development of an eye tracking technology, ETNA™, that shows promising use for neurological assessment of the progression of various neurological diseases. The ETNA™ technology is being trialed with patients living with various neurological diseases, such as multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, Friedreich Ataxia, and cancer-related cognitive impairment.

Business Type / 業種

R&D / 研究開発Others / その他

Business Domain / 分野

Information technology / ITMedical devices / 医薬機器

Technologies / 技術

Digital Biomarkers / デジタルバイオマーカーPharmacological/Safety evaluation / 薬効・薬理・安全性評価

Disease Area/疾患領域

Neurology & Psychiatry/中枢神経、精神疾患

Additional Information

Requested business parter / ご希望のビジネスパートナー 

Pharmaceuticals / 医薬品CRO /開発業務受託Neurology & Psychiatry/中枢神経、精神疾患Digital Biomarkers / デジタルバイオマーカー

Representatives

Chief Business Officer

Innodem Neurosciences

Marketplace (3)

  • Product

    ETNA-MS

    (ETNA™-MS) is a commercial stage software as a medical device (SaMD), Class II, intended to administer a non-invasive test allowing to track eye-movement metrics in adult patients and to provide MS condition monitoring,

    • License partner
    Author

    Chief Business Officer at Innodem Neurosciences

  • Product

    ETNA-AD

    ATNA-AD is the second Innodem product for early diagnosis of Alzheimer Disease. Ongoing development in Canada will allow to file for approval in Q1 2027.

    Author

    Chief Business Officer at Innodem Neurosciences

  • Product

    Ditch Pen

    The Ditch Pen is a medical device developped by a Canadian company aiming to help patients with smoking cessation

    • License partner
    • Investment/Finance
    Author

    Chief Business Officer at Innodem Neurosciences